Stockscreener 앱 받기
90.73
1.10%
0.99
시간 외 거래:
91.00
0.27
+0.30%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Franklin Resources Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Barclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Sleep Apnea Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Treatment Outlook | Axsome Therapeutics/Jazz Pharma, Bioprojet Pharma, Taisho Pharma - Barchart
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 4%Here's What Happened - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Lowered by State Street Corp - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 7.9% in November - MarketBeat
Axsome Therapeutics' SWOT analysis: strong growth, pipeline potential lift stock - Investing.com
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? - MSN
Captrust Financial Advisors Acquires Shares of 5,722 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,479 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Wellington Management Group LLP Acquires 8,125 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Fmr LLC Has $97.79 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Charles Schwab Investment Management Inc. Buys 12,778 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is RTW Investments LP's 2nd Largest Position - MarketBeat
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HighVista Strategies LLC Sells 20,650 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market - The Globe and Mail
Smoking Cessation and Nicotine Addiction Market Growth - openPR
PDT Partners LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
9,466 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fred Alger Management LLC - MarketBeat
Trend Tracker for (AXSM) - Stock Traders Daily
Bellevue Group AG Decreases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Eventide Asset Management LLC Has $74.40 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome: Focus On AXS-12 Targeting Narcolepsy, Just Released Positive Data (NASDAQ:AXSM) - Seeking Alpha
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Brokers Reduce Earnings Estimates for AXSM - MarketBeat
Cynosure Group LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Intech Investment Management LLC Makes New $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says - AOL
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
HC Wainwright Has Bullish Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome's AXS-12 shows efficacy in narcolepsy trial By Investing.com - Investing.com Canada
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy - MSN
Axsome Therapeutics eyes approval after Phase III narcolepsy win - Clinical Trials Arena
Positive Phase III data in narcolepsy from Axsome - The Pharma Letter
Axsome Therapeutics Announces AXS-12 Achieves Primary - GlobeNewswire
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week - Yahoo Finance
Axsome's AXS-12 shows efficacy in narcolepsy trial - Investing.com India
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis - Yahoo Finance
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy - The Manila Times
Loomis Sayles & Co. L P Acquires 29,497 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome's AXS-12 Shows 77% Reduction in Narcolepsy Attacks in Phase 3 Trial Success | AXSM Stock News - StockTitan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Brokerages - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome shares reiterate Buy rating on strong Q3 results By Investing.com - Investing.com UK
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet? - Simply Wall St
Eagle Asset Management Inc. Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Landscape Capital Management L.L.C. Makes New $585,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Invests $830,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories - Barchart
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 - openPR
Excessive Daytime Sleepiness Market to Witness Growth During the Forecast Period | Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio - The Globe and Mail
(AXSM) Long Term Investment Analysis - Stock Traders Daily
Axsome Therapeutics' SWOT analysis: strong pipeline, sales growth boost stock outlook - Investing.com
2.88%
2.65%
자본화:
|
볼륨(24시간):